career highlights
career highlights
Patrick Terry can be considered the godfather of personalized medicine in the age of genetics.
Professor, Medicine, Harvard Medical School
Scientific Director, Harvard-Partners Center for Genetics and Genomics.
Personalized Medicine Coalition/Harvard Symposium, 2014
somalogic, inc., boulder co
(Exit: SPAC Merger 2021)
chief commercial officer
- Crafted and operationalized multi-channel clinical strategy for their R&D proteomics asset.
- Built and mentored a 20-member team into a highly adaptive, cohesive, and innovative commercial group.
- Played an integral strategic role in operationalizing $150M pharmaceutical partnership investments.
- Secured a novel strategic partnership with a Japanese conglomerate for international market creation.
2019 - 2021
MEMED DIAGNOSTICS., Haifa, Israel
(Exit: IPO 20XX)
Co-Founder, Board Member, & Chief Commercial Officer
- Co-designed an innovative blood test that allows for rapid diagnosis of infection, thereby targeting antibiotics.
- Achieved recognition by the World Health Organization for pioneering solutions that will impact million lives.
- Scaled the organization from a 4-person startup to a successful private company now valued at over $1.5B.
2012 - 2021
INIVATA UK LTD., Cambridge, UK / Raleigh, NC
(Exit: Acquired)
Co-Founder, Independent Board Director, Chief Commercial Officer
Co-founded a new personalized medicine biotechnology startup out of Cambridge University and secured the needed risk capital funding and international investor buy-in to enable the company’s successful launch InVisionFirst®
- Co-designed an innovative blood test that allows for rapid diagnosis of infection, thereby targeting antibiotics.
- Achieved recognition by the World Health Organization for pioneering solutions that will impact million lives.
- Scaled the organization from a 4-person startup to a successful private company now valued at over $1.5B.
2015 - 2019
TECHNIC SOLUTIONS, Bethesda, MD / Cambridge, MA
(Exit: Acquired)
Founder, CEO, & Personalized Medicine Division Head
Consultant to 85+ multi-national life science client organizations in the area of applied science commercialization.
- Facilitated transitional activities following the acquisition of consulting company by Scientia Advisors.
- Created a recognized center-of-excellence for management consulting in the business community.
- Managed many multinational commercialization projects in Rx/Dx/MedTech/Digital Health.
- Managed a diverse and growing client base that enable Scientia Advisors to be acquired.
2008 - 2012
GENOMIC HEALTH, Palo Alto, CA / Geneva, Switzerland
(Exit: Acquired)
Founder, CEO, & Personalized Medicine Division Head
Created a new biotechnology company to drive precision medicine in better supporting patients living with cancer. Secured $154M in venture capital during a Silicon Valley recession. Leveraged a data-driven and personalized approach to medicine to develop continuously disruptive solutions in the management of clinical oncology.
- Successfully organized 800+ stakeholder groups across the United States into one diverse community focused on transforming personalized medicine approaches and patient experiences.
- Enabled advances in innovation that previously averaged 20 years to clinical adoption in just over five years.
- Educated and trained the cancer community in adopting a new treatment paradigm (OncoType DX®) that has saved millions of individuals from experiencing ineffective cytotoxic cancer treatments.
- Recognized for developing a new commercial paradigm for enabling the delivery of personalized medicine.